Acadian Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q1
Sell
-7,155
Closed -$3K 1860
2024
Q4
$3K Hold
7,155
﹤0.01% 1575
2024
Q3
$26K Sell
7,155
-19,235
-73% -$69.9K ﹤0.01% 1941
2024
Q2
$147K Sell
26,390
-26,056
-50% -$145K ﹤0.01% 1484
2024
Q1
$274K Sell
52,446
-235,109
-82% -$1.23M ﹤0.01% 1130
2023
Q4
$1.5M Buy
287,555
+50,653
+21% +$264K 0.01% 747
2023
Q3
$3.73M Buy
236,902
+12,326
+5% +$194K 0.02% 527
2023
Q2
$4.36M Buy
224,576
+9,145
+4% +$178K 0.02% 491
2023
Q1
$6.11M Sell
215,431
-16,156
-7% -$458K 0.03% 410
2022
Q4
$6.77M Sell
231,587
-79,633
-26% -$2.33M 0.03% 370
2022
Q3
$8.22M Buy
311,220
+124,347
+67% +$3.29M 0.05% 307
2022
Q2
$8.3M Buy
186,873
+47,178
+34% +$2.1M 0.04% 305
2022
Q1
$6.91M Buy
139,695
+33,816
+32% +$1.67M 0.03% 391
2021
Q4
$5.39M Sell
105,879
-23,551
-18% -$1.2M 0.02% 438
2021
Q3
$7.21M Sell
129,430
-132,273
-51% -$7.37M 0.03% 374
2021
Q2
$11.2M Buy
261,703
+48,694
+23% +$2.08M 0.04% 307
2021
Q1
$8.89M Buy
213,009
+41,525
+24% +$1.73M 0.03% 349
2020
Q4
$7.99M Buy
171,484
+2,785
+2% +$130K 0.03% 389
2020
Q3
$7.17M Buy
168,699
+50,643
+43% +$2.15M 0.03% 367
2020
Q2
$5.66M Buy
118,056
+30,043
+34% +$1.44M 0.02% 462
2020
Q1
$4.05M Buy
88,013
+64,413
+273% +$2.96M 0.02% 434
2019
Q4
$1.42M Sell
23,600
-6,893
-23% -$414K 0.01% 791
2019
Q3
$1.73M Sell
30,493
-4,380
-13% -$248K 0.01% 727
2019
Q2
$1.94M Buy
34,873
+30,725
+741% +$1.71M 0.01% 627
2019
Q1
$210K Buy
4,148
+1,140
+38% +$57.7K ﹤0.01% 1346
2018
Q4
$121K Buy
3,008
+1,356
+82% +$54.5K ﹤0.01% 1234
2018
Q3
$115K Buy
+1,652
New +$115K ﹤0.01% 1178
2018
Q1
Sell
-3,761
Closed -$201K 1871
2017
Q4
$201K Sell
3,761
-3,876
-51% -$207K ﹤0.01% 952
2017
Q3
$456K Buy
+7,637
New +$456K ﹤0.01% 799